Wainzua
Named-patient access overview. Wainzua is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Wainua (eplontersen) is the GalNAc-conjugated antisense oligonucleotide for hereditary transthyretin-mediated amyloidosis with polyneuropathy. It received FDA approval in December 2023 and is co-commercialized in the US under the Wainua brand by Ionis Pharmaceuticals and AstraZeneca; the underlying brand attribution in your home jurisdiction may use either name. For Saudi Arabia patients with confirmed hATTR-PN whose treating physician has recommended eplontersen, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Wainzua
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Wainzua is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Wainzua in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Wainzua
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.